We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
F star Therapeutics Inc | NASDAQ:FSTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.12 | 7.20 | 7.72 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
F-Star Therapeutics, Inc.
(Name of Subject Company)
F-Star Therapeutics, Inc.
(Names of Person Filing Statement)
Common Stock, Par Value $0.0001 Per Share
(Title of Class of Securities)
30315R107
(CUSIP Number)
Eliot Forster
Chief Executive Officer
Eddeva B920
Babraham Research Campus
Cambridge, CB22 3AT, United Kingdom
+44-1223-497400
(Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications
on Behalf of the Person Filing Statement)
Copies To:
William C. Hicks, Esq.
Matthew Gardella, Esq.
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo P.C.
One Financial Center
Boston, MA 02111
617-542-6000
☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Schedule 14D-9 filing relates solely to preliminary communications made before the commencement of a planned cash tender offer (the Offer) by invoX Pharma Limited, a private limited company organized under the laws of England and Wales (Parent) and Fennec Acquisition Incorporated, a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser), to acquire all of the issued and outstanding shares of the common stock, par value $0.0001 per share, of F-star Therapeutics, Inc., a Delaware corporation (the Company), to be commenced pursuant to the Agreement and Plan of Merger, dated as of June 22, 2022, by and among Parent, Purchaser, the Company and Sino Biopharmaceutical Limited, a company organized under the laws of the Cayman Islands (the Merger Agreement). Upon the consummation of the Offer, Purchaser will merge with and into the Company (the Merger) pursuant to Section 251(h) of the Delaware General Corporation Law with the Company as the surviving corporation.
| Exhibit 99.1: Email from Eliot Forster, Chief Executive Officer of the Company to commercial partners on June 23, 2022 |
| Exhibit 99.2: Email from Eliot Forster, Chief Executive Officer of the Company to staff on June 23, 2022 |
| Exhibit 99.3: Announcements by the Company and the Companys management via LinkedIn on June 23, 2022 |
| Exhibit 99.4: Announcements by the Company and the Companys management via Twitter on June 23, 2022 |
| Exhibit 99.5: Presentation by the Company at Employee Meeting on June 23, 2022 |
Forward-Looking Statements
This communication contains forward-looking statements. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans, will be and similar expressions. These forward-looking statements include, without limitation, statements related to the anticipated consummation of the acquisition of the Company and the timing and benefits thereof, and other statements that are not historical facts. These forward-looking statements are based on Parents and the Companys current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the parties ability to complete the transaction on the proposed terms and schedule; whether the tender offer conditions will be satisfied; whether sufficient stockholders of the Company tender their shares in the transaction; the outcome of legal proceedings that may be instituted against the Company and/or others relating to the transaction; the failure (or delay) to receive the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; and other risks related to the Companys business detailed from time-to-time under the caption Risk Factors and elsewhere in the Companys filings and reports filed with the U.S. Securities and Exchange Commission (the SEC), including the Companys Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent quarterly and current reports filed with the SEC. The risks and uncertainties may be amplified by the Russian invasion of Ukraine and the ongoing COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which these factors impact the Companys business, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration of the conflict in Ukraine, the duration and spread of the COVID-19 outbreak, the spread of any new variants of COVID-19, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. The Company undertakes no duty or obligation to update any forward-looking statements contained in this communication as a result of new information, future events or changes in their expectations, except as required by law.
Additional Information and Where to Find It
The Offer has not yet commenced, and this communication is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of the Company or any other securities. On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed with the SEC by Parent and Purchaser, and a Solicitation / Recommendation Statement on Schedule 14D-9 will be filed with the SEC by the Company. The offer to purchase shares of Company common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION / RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which will be named in the tender offer statement. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the Investors section of the Companys website at www.f-star.com.
1 Year F star Therapeutics Chart |
1 Month F star Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions